Posts

Showing posts from February, 2023

She also called the last-minute offer a "blatant effort to influence the jury pool" and "yet another bad faith and legally frivolous delay tactic."

  She also called the last-minute offer a "blatant effort to influence the jury pool" and "yet another bad faith and legally frivolous delay tactic."  It's unclear if the judge will allow the last-minute DNA sample. Judge Lewis A. Kaplan (no relation to Carroll's attorney) has already complained multiple times about Trump's side dragging the case out with delay after delay.Kaplan, the attorney, explained in her response Friday that she and other attorneys for Carroll ultimately decided not to fight Trump over his DNA because they anticipated appeals that could slow down the process.  "Carroll, now 79 years old, has built her case with powerful additional evidence and is ready to prove Trump's liability before a jury; she should not be prejudiced by Trump's latest gambit to violate the Court's orders and uproot the trial date," her lawyer wrote.  Tacopina declined to comment on Friday's filing. Kaplan said the response " spe...

Overall CR rate (CR + CRi), CR, and subsequent allogeneic stem cell transplant (alloSCT) rates remained unchanged

  Overall CR rate (CR + CRi), CR, and subsequent allogeneic stem cell transplant (alloSCT) rates remained unchanged since the prior data cut at 71%, 56%, and 20%, respectively. Median relapse-free survival (RFS) was censored and not censored at subsequent alloSCT at 11.6 and 11.7 months, respectively. At the data cutoff, 36% of patients (28) were still alive, with a median OS of 25.6 months. Price Action: GILD shares are up 0.46% at $86.06 on the last check Thursday. Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.This article Kite's Tecartus CAR T-Cell Therapy Demonstrates Durable Overall Survival Benefit In Leukemia Settings originally appeared on Benzinga.com